A length-dependent neuropathy with pain in the feet is a common complication of diabetes (painful diabetic neuropathy). It was hypothesized that pain may arise from sensitized-hyperactive cutaneous nociceptors, and that this abnormal signaling may be reduced by topical administration of the a 2 -adrenergic agonist, clonidine, to the painful area. This was a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial. Nociceptor function was measured by determining the painfulness of 0.1% topical capsaicin applied to the pretibial area of each subject for 30 minutes during screening. Subjects were then randomized to receive 0.1% topical clonidine gel (n = 89) or placebo gel (n = 90) applied 3 times a day to their feet for 12 weeks. The difference in foot pain at week 12 in relation to baseline, rated on a 0-10 numerical pain rating scale (NPRS), was compared between groups. Baseline NPRS was imputed for missing data for subjects who terminated the study early. The subjects treated with clonidine showed a trend toward decreased foot pain compared to the placebo-treated group (the primary endpoint; P = 0.07). In subjects who felt any level of pain to capsaicin, clonidine was superior to placebo (P < 0.05). In subjects with a capsaicin pain rating P2 (0-10, NPRS), the mean decrease in foot pain was 2.6 for active compared to 1.4 for placebo (P = 0.01). Topical clonidine gel significantly reduces the level of foot pain in painful diabetic neuropathy subjects with functional (and possibly sensitized) nociceptors in the affected skin as revealed by testing with topical capsaicin. Screening for cutaneous nociceptor function may help distinguish candidates for topical therapy for neuropathic pain. Ó
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Introduction
A length-dependent neuropathy is one of the most common complications of diabetes. Pain, typically felt in the feet, is a common feature. The analgesic efficacy of oral medications such as pregabalin and duloxetine in painful diabetic neuropathy (PDN) is highly variable, and many patients have difficulty with side effects [25] . It is therefore desirable to find alternative therapies. Prior reports from studies in animals and man have suggested that clonidine may be effective in relieving neuropathic pain when applied topically to the painful area [6, 17] . Clonidine is an a 2 -adrenergic receptor agonist that was originally approved as an oral product to treat hypertension. Intrathecally applied clonidine was later shown to produce analgesia for both acute and chronic pain [10] . Alpha-2 receptors are also present on nociceptors in the epidermis [26] . Activation of these G-protein-coupled receptors leads to release of an inhibitory G-protein which, in turn, downregulates adenylate cyclase and other second messengers thought to play a role in initiating and maintaining the abnormal excitability of nociceptors [16] . The origin of neuronal signals leading to pain in PDN is unknown, though nociceptors expressed in the skin are a potential target [3] . Given the robust expression of a 2 receptors in cutaneous nociceptors, evidence that nociceptors in the skin may be sensitized in neuropathic pain models, and prior behavioral and clinical data indicating analgesic effects of clonidine, a double-blind randomized study was performed to determine efficacy, tolerability, and safety of topical clonidine to treat PDN. In some
